Skip to main content
SpringerLink
Log in

Combination therapy is preferred for the first-line treatment of hypertension in high-risk patients

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig 1
Table II
Table III

References

  1. Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 2009; 69(13): 1761–76

    Article  PubMed  CAS  Google Scholar 

  2. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Invest 2008; 28(11): 713–34

    Article  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(9): 1105–87

    Article  PubMed  CAS  Google Scholar 

  5. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326(7404): 1427–31

    Article  PubMed  CAS  Google Scholar 

  6. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2000; 4(6): 393–404

    Google Scholar 

  7. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50(2): 299–305

    Article  PubMed  CAS  Google Scholar 

  8. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98(7): 890–4

    Article  PubMed  CAS  Google Scholar 

  9. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906

    Article  PubMed  Google Scholar 

  10. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28

    Article  PubMed  CAS  Google Scholar 

  11. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1(1): 43–50

    Article  PubMed  CAS  Google Scholar 

  12. Black HR, Levy DG, Crikelair N, et al. Predictive age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens 2008 (6); 2: 476–83

    Article  PubMed  Google Scholar 

  13. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366(9496): 1545–53

    Article  PubMed  CAS  Google Scholar 

  14. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24(11): 2131–41

    Article  PubMed  CAS  Google Scholar 

  15. Naylor WG. The potential for added benefits with β-blockers and calcium antagonists in treating cardiovascular disorders. Drugs 1988; 35Suppl. 4: 1–8

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Combination therapy is preferred for the first-line treatment of hypertension in high-risk patients. Drugs Ther. Perspect 26, 17–20 (2010). https://doi.org/10.2165/11205340-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205340-000000000-00000

Search

Navigation